#1 Clinical Trials Search in Europe

Dexrazoxane

Dexrazoxane is a drug being studied in clinical trials for its potential to protect the heart from damage caused by certain cancer treatments, particularly anthracycline chemotherapy drugs. This article explores how dexrazoxane is being investigated to prevent heart problems in cancer patients and treat accidental extravasation of chemotherapy drugs.

Table of Contents

What is Dexrazoxane?

Dexrazoxane is a medication primarily used to protect the heart from damage caused by certain chemotherapy drugs, particularly anthracyclines like doxorubicin. It’s also known by brand names such as Zinecard, Totect, and Cardioxane[6]. Dexrazoxane acts as a cardioprotectant, which means it helps shield the heart from potential harm during cancer treatment[1].

How Dexrazoxane Works

Dexrazoxane works in several ways to protect the heart:

  • It reduces the formation of harmful reactive oxygen species (ROS), which are unstable molecules that can damage heart cells[2].
  • It helps prevent apoptosis, which is a process of programmed cell death that can affect heart muscle cells[2].
  • It targets an enzyme called Topoisomerase 2b in the blood, which is thought to play a role in heart damage caused by certain chemotherapy drugs[1].
By protecting the heart, dexrazoxane allows patients to receive higher doses of chemotherapy or continue treatment for longer periods, potentially improving their cancer outcomes.

Conditions Treated with Dexrazoxane

Dexrazoxane is used in various medical scenarios:

  • Cancer Treatment: It’s primarily used alongside chemotherapy for various cancers, including breast cancer and soft tissue sarcomas[3][6].
  • Anthracycline Extravasation: Dexrazoxane can be used to treat accidental leakage of anthracycline chemotherapy drugs into surrounding tissues, which can cause severe damage[4].
  • Congenital Heart Surgery: Research is being conducted to see if dexrazoxane can protect the hearts of infants and young children during heart surgery[5].

How Dexrazoxane is Administered

Dexrazoxane is typically given as an intravenous (IV) infusion, which means it’s delivered directly into a vein. The dosage and schedule can vary depending on the specific treatment plan:

  • For cancer treatment, it’s often given before the chemotherapy drug, usually at a ratio of 10 parts dexrazoxane to 1 part doxorubicin[6].
  • In cases of anthracycline extravasation, it may be given once daily for three consecutive days[4].
  • For heart surgery in infants, researchers are studying various dosing regimens[5].
The exact dosage and timing will be determined by your healthcare provider based on your specific condition and treatment plan.

Current Clinical Trials

Several clinical trials are currently exploring new uses for dexrazoxane:

  • Testing its effectiveness in preventing heart failure in breast cancer patients receiving doxorubicin[1].
  • Investigating its use in protecting the hearts of infants and young children during congenital heart surgery[5].
  • Evaluating its role in treating accidental extravasation (leakage) of anthracycline chemotherapy drugs[4].
  • Studying its use alongside other cancer treatments for soft tissue sarcomas[6].
These trials aim to expand our understanding of how dexrazoxane can be used to protect patients from various forms of heart damage.

Potential Side Effects

While dexrazoxane is generally well-tolerated, it may cause some side effects. Common side effects can include:

  • Nausea or vomiting
  • Fatigue
  • Decreased white blood cell count (which can increase the risk of infections)
Your healthcare provider will monitor you closely for any side effects and adjust your treatment as necessary. It’s important to report any unusual symptoms or side effects to your doctor promptly[6].

Aspect Details
Primary Use Cardioprotection during anthracycline chemotherapy
Secondary Use Treatment of anthracycline extravasation
Administration Intravenous infusion, typically before chemotherapy
Patient Groups Adults and children with various cancers, including breast cancer and soft tissue sarcoma
Dosage Range Varies by trial, often 10:1 ratio to anthracycline dose
Outcome Measures Heart function, progression-free survival, reduction in tissue damage
Safety Monitoring Blood tests, cardiac function tests, adverse event reporting

FAQ

  • What is the main purpose of using dexrazoxane in cancer treatment? The main purpose of using dexrazoxane in cancer treatment is to protect the heart from damage caused by anthracycline chemotherapy drugs. It acts as a cardioprotective agent to reduce the risk of heart problems that can occur as a side effect of certain cancer treatments.
  • How is dexrazoxane administered to patients? Dexrazoxane is typically administered intravenously (through an IV) before or after anthracycline chemotherapy. The dosage and timing can vary depending on the specific trial protocol, but it's often given as an infusion over 15-30 minutes prior to chemotherapy.
  • What types of cancer patients are being studied with dexrazoxane? Clinical trials are studying dexrazoxane in various cancer patients, including those with breast cancer, soft tissue sarcoma, and children with congenital heart defects undergoing cancer treatment. It's being investigated in both adult and pediatric populations.
  • Can dexrazoxane help with chemotherapy drug extravasation? Yes, some clinical trials are investigating dexrazoxane as a treatment for accidental extravasation (leakage into surrounding tissue) of anthracycline chemotherapy drugs. It may help prevent tissue damage and necrosis caused by the leaked drugs.
  • Are there any potential side effects of dexrazoxane? While dexrazoxane is generally well-tolerated, potential side effects are being monitored in clinical trials. These may include changes in blood cell counts, nausea, and vomiting. The trials are designed to assess both the efficacy and safety of dexrazoxane in various patient populations.

Ongoing Clinical Trials on Dexrazoxane

  • Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Gemtuzumab Ozogamicin and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated drugs:
    Belgium Denmark Estonia Finland Iceland Latvia +6

Glossary

  • Anthracycline: A class of chemotherapy drugs used to treat various types of cancer. Examples include doxorubicin and epirubicin. These drugs can potentially cause heart damage as a side effect.
  • Cardiotoxicity: Damage to the heart muscle or changes in heart function caused by medications or other substances. In cancer treatment, it often refers to heart problems caused by certain chemotherapy drugs.
  • Extravasation: The accidental leakage of intravenous (IV) medications into the surrounding tissue instead of into the bloodstream. With certain chemotherapy drugs, this can cause severe tissue damage.
  • Cardioprotective: Referring to something that protects the heart from damage. In this context, dexrazoxane is being studied for its cardioprotective effects against chemotherapy-induced heart damage.
  • Topoisomerase 2: An enzyme involved in DNA replication and cell division. Some chemotherapy drugs target this enzyme, and dexrazoxane may work by affecting its activity.
  • Necrosis: The death of body tissue due to lack of blood flow or other traumatic injury. In the context of extravasation, it refers to tissue death caused by leaked chemotherapy drugs.
  • Ejection Fraction: A measurement of how well the heart is pumping blood. It's often used to assess heart function in patients receiving potentially cardiotoxic treatments.
  • Cardiopulmonary Bypass: A technique used in heart surgery where a machine temporarily takes over the function of the heart and lungs during the operation.

References

  1. https://clinicaltrials.gov/study/NCT03930680
  2. https://clinicaltrials.gov/study/NCT02519335
  3. https://clinicaltrials.gov/study/NCT00955890
  4. https://clinicaltrials.gov/study/NCT01596088
  5. https://clinicaltrials.gov/study/NCT04997291
  6. https://clinicaltrials.gov/study/NCT02584309